Sigrid V. Carlsson, MD, PhD, MPH, presented “Year in Review: Emerging Data and Advances in Screening” during the 7th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on September 21, 2023.
How to cite: Carlsson, Sigrid V. “Year in Review: Emerging Data and Advances in Screening.” September 21, 2023. Accessed Nov 2024. https://grandroundsinurology.com/year-in-review-emerging-data-and-advances-in-screening/
Year in Review: Emerging Data and Advances in Screening – Summary
Sigrid V. Carlsson, MD, PhD, MPH, presents an overview of advances and emerging trends in prostate cancer screening in 2023. Dr. Carlson begins by presenting data supporting the continued use of routine PSA tests for prostate cancer screening, while highlighting the need for more granular risk stratification based on individual PSA baselines to bridge existing mortality gaps based on individual PSA baselines.
Dr. Carlsson then examines current trends in using genetics for biopsy risk stratification. She presents evidence that the polygenic risk scores which predict prostate cancer incidence are not useful in predicting mortality. She then discusses the role of biomarkers, risk calculators, and MRI-based screening techniques that are available pre-biopsy.
Turning to emerging data, Dr. Carlsson concludes by presenting a selection of national and international ongoing efforts to develop risk-stratified algorithms for early prostate cancer detection. She touches on the European Union’s “Praise U” initiative, Germany’s “PROBASE” trial, the Stockholm 3 trial, and the ProScreen study.
The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a unique multi-disciplinary forum organized to inform the key health care stakeholders about the emerging advances in clinical case and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization. The mission of the Summit is to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of novel observation strategies (e.g., active surveillance, or AS) and therapeutic interventions.
ABOUT THE AUTHOR
Sigrid V. Carlsson, MD, PhD, MPH, is Director of Clinical Research at Memorial Sloan Kettering Cancer Center’s (MSKCC) Josie Robertson Surgery Center and Assistant Attending Epidemiologist, with dual appointments in MSKCC’s Departments of Surgery (Urology Service) and Epidemiology and Biostatistics. Her line of research focuses on screening and early detection of prostate cancer, including multiplex testing and risk-stratified strategies that incorporate clinical information, biomarkers and magnetic resonance imaging, as recently funded by an NIH/NCI U01 award (PI: Carlsson).
Dr. Carlsson also serves as Associate Professor of Experimental Urology affiliated with the Institute of Clinical Sciences, Sahlgrenska Academy, Gothenburg University, in Sweden, where she is an investigator of two large randomized controlled trials of prostate cancer screening (GOTEBORG-1&2), as recently published in the New England Journal of Medicine (Hugosson J, et al. N Engl J Med 2022). In addition, Dr. Carlsson is Adjunct Senior Lecturer in the Department of Translational Medicine in the Division of Urological Cancers in the Medical Faculty at Lund University, Lund, Sweden.
Dr. Carlsson recently completed a K22 career development award from the NIH/NCI to improve shared decision-making for breast and prostate cancer screening. She serves on the National Comprehensive Cancer Network (NCCN) and is a panel member for the American Urological Association (AUA) guidelines for early detection of prostate cancer. Before pursuing postdoctoral studies in urologic oncology at MSKCC, Dr. Carlsson was a physician in Sweden. She earned her MD and PhD from Gothenburg University in Sweden and earned an MPH from Harvard TH Chan School of Public Health in Boston, Massachusetts.
